Defining HIV-1 Vif residues that interact with CBFβ by site-directed mutagenesis

Virology

Volumn 449, Issue , 2014, Pages 82-87

  Matsui, Yusuke ^a   Shindo, Keisuke ^a   Nagata, Kayoko ^a   Io, Katsuhiro ^a   Tada, Kohei ^a   Iwai, Fumie ^a   Kobayashi, Masayuki ^a   Kadowaki, Norimitsu ^a   Harris, Reuben S ^b   Takaori Kondo, Akifumi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

CBF ; HIV 1; Host factors; Interaction; Vif

Indexed keywords

ALANINE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CORE BINDING FACTOR BETA; VIF PROTEIN; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RESIDUE ANALYSIS; SITE DIRECTED MUTAGENESIS; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CBFΒ; HIV-1; HOST FACTORS; INTERACTION; VIF;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; CONSERVED SEQUENCE; CORE BINDING FACTOR BETA SUBUNIT; CYTIDINE DEAMINASE; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84888261024     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.11.004     Document Type: Article

References (36)

1. Albin J.S., Haché G., Hultquist J.F., Brown W.L., Harris R.S. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J. Virol. 2010, 84(19):10209-10219.
2. Bergeron J.R., Huthoff H., Veselkov D.A., Beavil R.L., Simpson P.J., Matthews S.J., Malim M.H., Sanderson M.R. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog 2010, 6(6):e1000925.
3. Chelico L., Pham P., Calabrese P., Goodman M.F. APOBEC3G DNA deaminase acts processively 3'→5' on single-stranded DNA. Nat. Struct. Mol. Biol. 2006, 13(5):392-399.
4. Chen G., He Z., Wang T., Xu R., Yu X.F. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 2009, 83(17):8674-8682.
5. Dang Y., Davis R.W., York I.A., Zheng Y.H. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 2010, 84(11):5741-5750.
6. Dang Y., Wang X., Zhou T., York I.A., Zheng Y.H. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 2009, 83(17):8544-8552.
7. Dussart S., Courcoul M., Bessou G., Douaisi M., Duverger Y., Vigne R., Decroly E. The Vif protein of human immunodeficiency virus type 1 is posttranslationally modified by ubiquitin. Biochem. Biophys. Res. Commun. 2004, 315(1):66-72.
8. Fujita M., Akari H., Sakurai A., Yoshida A., Chiba T., Tanaka K., Strebel K., Adachi A. Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microb. Infect. 2004, 6(9):791-798.
9. Fujita M., Sakurai A., Yoshida A., Miyaura M., Koyama A.H., Sakai K., Adachi A. Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif. J. Virol. 2003, 77(2):1626-1632.
10. Gabuzda D.H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W.A., Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 1992, 66(11):6489-6495.
11. Gabuzda D.H., Li H., Lawrence K., Vasir B.S., Crawford K., Langhoff E. Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J. Acquir. Immune Defic. Syndr. 1994, 7(9):908-915.
12. Haché G., Shindo K., Albin J.S., Harris R.S. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr. Biol. 2008, 18(11):819-824.
13. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113(6):803-809.
14. He Z., Zhang W., Chen G., Xu R., Yu X.F. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 2008, 381(4):1000-1011.
15. Hultquist J.F., Binka M., LaRue R.S., Simon V., Harris R.S. Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. J, Virol, 2011, 86(5):2874-2877.
16. Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L., Brown W.L., Harris R.S. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 2011, 85(21):11220-11234.
17. Hultquist J.F., McDougle R.M., Anderson B.D., Harris R.S. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor beta on genetically distinct surfaces. AIDS Res. Hum. Retroviruses 2012, 28(12):1543-1551.
18. Izumi T., Takaori-Kondo A., Shirakawa K., Higashitsuji H., Itoh K., Io K., Matsui M., Iwai K., Kondoh H., Sato T., Tomonaga M., Ikeda S., Akari H., Koyanagi Y., Fujita J., Uchiyama T. MDM2 is a novel E3 ligase for HIV-1 Vif. Retrovirology 2009, 6:1.
19. Jäger S., Kim D.Y., Hultquist J.F., Shindo K., LaRue R.S., Kwon E., Li M., Anderson B.D., Yen L., Stanley D., Mahon C., Kane J., Franks-Skiba K., Cimermancic P., Burlingame A., Sali A., Craik C.S., Harris R.S., Gross J.D., Krogan N.J. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 2011, 481(7381):371-375.
20. Kim D.Y., Kwon E., Hartley P.D., Crosby D.C., Mann S., Krogan N.J., Gross J.D. CBFbeta stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol. Cell 2013, 49(4):632-644.
21. Luo K., Xiao Z., Ehrlich E., Yu Y., Liu B., Zheng S., Yu X.F. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Nat. Acad. Sci. U.S.A. 2005, 102(32):11444-11449.
22. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 2003, 9(11):1398-1403.
23. Mehle A., Goncalves J., Santa-Marta M., McPike M., Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 2004, 18(23):2861-2866.
24. Mehle A., Thomas E.R., Rajendran K.S., Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 2006, 281(25):17259-17265.
25. Pery E., Rajendran K.S., Brazier A.J., Gabuzda D. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 2009, 83(5):2374-2381.
26. Russell R.A., Pathak V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 2007, 81(15):8201-8210.
27. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418(6898):646-650.
28. Sheehy A.M., Gaddis N.C., Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 2003, 9(11):1404-1407.
29. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., Uchiyama T. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 2003, 278(45):44412-44416.
30. Shirakawa K., Takaori-Kondo A., Kobayashi M., Tomonaga M., Izumi T., Fukunaga K., Sasada A., Abudu A., Miyauchi Y., Akari H., Iwai K., Uchiyama T. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex. Virology 2006, 344(2):263-266.
31. Stopak K., de Noronha C., Yonemoto W., Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 2003, 12(3):591-601.
32. Wolfe L.S., Stanley B.J., Liu C., Eliason W.K., Xiong Y. Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. J Virol 2010, 84(14):7135-7139.
33. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302(5647):1056-1060.
34. Yu Y., Xiao Z., Ehrlich E.S., Yu X., Yu X.F. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 2004, 18(23):2867-2872.
35. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424(6944):94-98.
36. Zhang W., Du J., Evans S.L., Yu Y., Yu X.F. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 2011, 481(7381):376-379.